Akari Therapeutics (AKTX) Tax Provisions (2025 - 2026)

Akari Therapeutics (AKTX) reported Tax Provisions of -$859000.0 for Q1 2026, down 1110.59% sequentially from $85000.0 in Q4 2025.

Akari Therapeutics (AKTX) Tax Provisions (2025 - 2026) Analysis & Trends

Akari Therapeutics (AKTX) has 2 years of Tax Provisions data on file, last reported at -$859000.0 in Q1 2026.

For the quarter ending Q1 2026, Tax Provisions changed N/A year-over-year to -$859000.0; the trailing twelve-month figure through Mar 2026 stood at -$1.9 million (changed N/A YoY), and the FY2025 full-year result was -$1.0 million, changed N/A from the prior year.
Tax Provisions slipped to -$859000.0 in Q1 2026, from $85000.0 in the prior quarter.
In the past five years, Tax Provisions ranged from a high of $85000.0 in Q4 2025 to a low of -$1.1 million in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Taxes (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-	125,146.46
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-859,000.00
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn	31.86 Mn
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn	221.50 Mn
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn	104.00 Mn
7	Belite Bio	61.40 Bn	61.40 Bn	-	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn	-60.00 Mn
9	Revolution Medicines	37.37 Bn	37.37 Bn	-	-
10	Alnylam Pharmaceuticals	36.08 Bn	33.07 Bn	959.66 Mn	15.66 Mn

Download Data